http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_25dc76036e95da995451601fbb60801d
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Ritchie |
| name | Rebecca H. Ritchie Rebecca H Ritchie |
| given-name | Rebecca H Rebecca H. |
| organization-name | Department of Physiology University of Melbourne Melbourne Victoria Australia Heart Failure Pharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (C.X.Q., R.H.R.). Department of Physiology, University of Melbourne, Melbourne, VIC 3010, Australia.; Heart Failure Pharmacology, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 8008, Australia.; Department of Pharmacology, College of Osteopathic Medicine, University of New England, Biddeford, ME 04005, USA. Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia; Department of Pharmacology and Therapeutics, The University of Melbourne, Parkville, Victoria 3010, Australia; Department of Medicine, Monash University, Clayton, Victoria 3800, Australia Heart Failure Pharmacology Laboratory Basic Science Domain Baker Heart and Diabetes Institute Melbourne Victoria Australia From the Goethe University, Frankfurt am Main, Germany (F. Spallotta, C.C., S.A., S.Z., D.S., F. Schnütgen, H.v.M., A.F., I.F., A.M.Z., C.G.); University of Turin, Torino, Italy (D.G., M. Cocco, R.M., A.D.S., M.A., M. Collino, M. Bertinaria); Istituto Italiano di Tecnologia CLNS@Sapienza Rome, Italy (M.M.); Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany (C.K., S.G., T.B.); Università Cattolica del Sacro Cuore, Rome, Italy (S.N.); Karolinska Institutet, Huddinge, Sweden (V.A.... From the Howard Florey Institute, Parkville, Victoria, Australia. Heart Failure Pharmacology, Baker IDI Heart and Diabetes Institute, Victoria, Australia Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, VIC, Australia. Department of Heart Failure Pharmacology, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia. Pharmacology, University of Melbourne, Victoria;; Heart Failure Pharmacology, Baker IDI Heart and Diabetes Institute, Victoria, Australia Heart Failure Pharmacology Baker Heart and Diabetes Institute Melbourne VIC Australia; Department of Diabetes Central Clinical School, Monash University Melbourne VIC Australia; Department of Pharmacology and Therapeutics University of Melbourne Melbourne VIC Australia Baker IDI Heart and Diabetes Institute, Melbourne, Australia; From the Baker IDI Heart and Diabetes Institute (N.J.S., H.-W.C., H.Q., A.M.B., R.H.R., W.G.T.), Prahran, Victoria, Australia; School of Biomedical Sciences (H.-W.C., A.M.B., W.G.T.), University of Queensland, St Lucia, Queensland, Australia; Growth Control and Differentiation Program (K.M.H., R.B.P., R.D.H.), Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Centenary Institute (F.J.W.), Camperdown, New South Wales, Australia. From the Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia, and the Department of Medicine, Monash University, Melbourne, Victoria, Australia. Baker IDI Heart & Diabetes Institute, Melbourne, Australia 1Heart Failure PharmacologyBaker Heart & Diabetes Institute, Melbourne, Victoria, Australia; 2Central Clinical SchoolMonash University, Melbourne, Victoria, Australia Heart Failure Pharmacology, Baker Heart & Diabetes Institute, Melbourne, Vic 3004, Australia; Department of Medicine (Central Clinical School), Monash University, Melbourne, Vic 3004, Australia Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia; Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria 3010, Australia; Department of Diabetes, Central Clinical School, Monash University, Clayton, Victoria 3800, Australia; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia Heart Failure Pharmacology Baker IDI Heart & Diabetes Institute Melbourne Vic. Australia; Department of Medicine Monash University Clayton Vic. Australia Howard Florey Institute and Baker IDI Heart & Diabetes Institute Melbourne; Department of Medicine Monash University Clayton Program in Molecular and Cellular Cardiology, Department of Internal Medicine, Wayne State University and Detroit Veterans Affairs Medical Center, Detroit 48201; and Howard Florey Institute, University of Melbourne, Victoria, Australia; Baker Heart Research Institute, Melbourne, Victoria, Australia Molecular Pharmacology Laboratory, Monash University, Alfred Hospital, Melbourne, Australia.; Department of Pharmacology, The University of Melbourne, Monash University, Alfred Hospital, Melbourne, Australia. From Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville Campus, Victoria, Australia (R.H.R.) From the Program in Molecular and Cellular Cardiology, Departments of Medicine and Otolaryngology, Harper Hospital, Detroit, Mich; the VA Medical Center, Boston University Medical Center, Boston, Mass (J.K.G.); and the Arrhythmia Center/Sinai Hospital (M.H.L.) and Wayne State University School of Medicine, Detroit, Mich (J.D.M.). Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria 3004, Australia; Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Victoria 3010, Australia; Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria 3004, Australia Baker IDI Heart and Diabetes Institute Melbourne Victoria Australia Heart Failure Pharmacology Baker Heart & Diabetes Institute Melbourne VIC Australia; Department of Diabetes Monash University Clayton VIC Australia Heart Failure Pharmacology, Baker Heart & Diabetes Institute, Melbourne, Australia.; Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Australia.; Department of Medicine (Central Clinical School), Monash University, Melbourne, Australia. Heart Failure Pharmacology Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, VIC, Australia; Department of Medicine, Monash University, Clayton, VIC, Australia Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia;; Department of Medicine, Monash University, Clayton, Victoria, Australia; and From the Division of Diabetes, Lipoproteins, and Metabolism (R.C., J.M.F., M.C.T., V.T., W.C.B., C.T., M.E.C., R.H.R.), Baker Heart Research Institute, Prahran, Victoria, Australia; the Department of Medicine, University of Melbourne, Austin and the Repatriation Medical Centre (R.G.D., M.E.C., L.M.B.), Heidelberg, Australia; and Diabetes Centre (S.M.T.), Royal Prince Alfred Hospital, Camperdown, Australia. Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia Program in Molecular and Cellular Cardiology, Department of Internal Medicine, Wayne State University, and the John D. Dingall Department of Veterans Affairs Medical Center, Detroit, Michigan 48201 From the Departments of Heart Failure Pharmacology (N.C., Y.G.W., S.R., C.Q., R.H.R.) and Experimental Cardiology (H.K. X.J.D.), Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia; and Departments of Pharmacology (Y.G.W., B.K.K.-H.) and Medicine (K.H., X.-J.D., R.H.R.), Monash University, Clayton, Victoria, Australia. Heart Failure Pharmacology Baker IDI Heart and Diabetes Institute Melbourne Australia; Department of Medicine Monash University Clayton Victoria Australia |
Incoming Links
Total number of triples: 156.